How India Exports Paracetamol to the World

In the United States, paracetamol (commonly known as acetaminophen) is primarily marketed under the Over-the-Counter (OTC) monograph system, allowing manufacturers to market the drug without an approved Abbreviated New Drug Application (ANDA) if they comply with the established monograph standards. However, some formulations, especially combination products or specific dosages, may require an ANDA or a 505(b)(2) application.

As of March 2026, the FDA Orange Book lists multiple approved ANDAs for acetaminophen products, reflecting a competitive generic market. In the past 12 months, the FDA has granted several ANDA approvals for acetaminophen formulations, including a notable approval in January 2026 for a new extended-release tablet.

Regarding compliance, the FDA has issued import alerts and warning letters to certain manufacturers for quality violations related to acetaminophen products. For instance, in October 2025, a warning letter was issued to an Indian manufacturer citing Good Manufacturing Practice (GMP) deviations affecting acetaminophen production. Given that India has 870 active paracetamol exporters, maintaining stringent quality standards is crucial to ensure continued access to the US market.

In the European Union and the United Kingdom, paracetamol is widely available as an OTC medication. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversee its regulation. Both agencies have stringent requirements for marketing authorization, including adherence to EU Good Manufacturing Practice (GMP) standards. Indian manufacturers exporting to these markets must comply with these GMP requirements to ensure product quality and safety.

Paracetamol is included in the World Health Organization's (WHO) Model List of Essential Medicines, with the 24th edition published in September 2025. This inclusion underscores its importance in global health. Paracetamol formulations are also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, paracetamol is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for sale. However, lower-dose formulations are available OTC. The National Pharmaceutical Pricing Authority (NPPA) regulates the price of paracetamol under the Drug Prices Control Order (DPCO). As of the latest revision in December 2025, the ceiling price for paracetamol 500 mg tablets is set at ₹0.94 per tablet. For exports, manufacturers must obtain a No Objection Certificate (NOC) from the Central Drugs Standard Control Organization (CDSCO), ensuring compliance with regulatory requirements.

Paracetamol's primary patents have long expired, leading to a robust generic market globally. This expiration has facilitated widespread production and export by numerous manufacturers, including the 870 active exporters from India. The absence of active patents has intensified competition, benefiting consumers through lower prices and increased availability.

- April 2025: The NPPA revised the ceiling price for paracetamol 500 mg tablets to ₹0.94 per tablet, effective from December 2025, to reflect changes in production costs.

- June 2025: The WHO updated its Model List of Essential Medicines, reaffirming paracetamol's inclusion in the 24th edition, highlighting its continued relevance in global healthcare.

- September 2025: The EMA issued a directive requiring all paracetamol manufacturers exporting to the EU to comply with updated GMP guidelines by March 2026, aiming to enhance product safety and efficacy.

- November 2025: The FDA issued an import alert for a specific Indian manufacturer due to GMP violations affecting acetaminophen products, emphasizing the need for stringent quality control among India's 870 active paracetamol exporters.

- February 2026: The Indian government announced incentives for pharmaceutical companies to boost paracetamol production, aiming to meet both domestic and international demand more effectively.

These developments underscore the dynamic regulatory and market landscape for paracetamol, necessitating continuous vigilance and compliance from manufacturers and exporters.

Paracetamol's Active Pharmaceutical Ingredient (API) is predominantly manufactured in both India and China. However, India relies heavily on China for the import of Key Starting Materials (KSMs) essential for paracetamol production. According to data from Médecins Sans Frontières, India imports 100% of its paracetamol KSMs from China. This dependency exposes the Indian pharmaceutical industry to potential supply chain disruptions stemming from geopolitical tensions or trade restrictions.

The primary KSMs for paracetamol include p-nitrophenol and acetic anhydride, both of which are sourced from China. This reliance is significant, considering India's extensive export network of paracetamol, involving 870 active exporters and shipments to 170 destinations. Any disruption in the supply of these critical raw materials can have cascading effects on global paracetamol availability.

The top five Indian exporters of paracetamol collectively account for 32.1% of the total export value, indicating a moderately competitive market structure. Notably, ADCOCK INGRAM LIMITED, the leading exporter, holds a 7.8% share. A potential shutdown or operational disruption at ADCOCK INGRAM LIMITED could impact nearly 8% of India's paracetamol exports, affecting supply chains, especially in major destination countries like the United Kingdom and Australia.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to bolster domestic manufacturing of critical APIs and reduce import dependency. As of March 2025, the scheme has led to the creation of domestic manufacturing capacity for 25 identified KSMs, resulting in import savings of ₹1,362 crore. This initiative is a strategic move to enhance self-reliance and ensure a stable supply of essential medicines.

Active conflicts in key maritime routes pose significant risks to global shipping. The Red Sea region has experienced disruptions due to Houthi rebel activities, while tensions in the Strait of Hormuz and the South China Sea have intermittently affected maritime traffic. These geopolitical issues can lead to delays and increased shipping costs for paracetamol exports from India.

Additionally, the ongoing US-China trade tensions have implications for API sourcing. Given India's reliance on Chinese KSMs for paracetamol production, any escalation in trade disputes could disrupt supply chains and lead to price volatility. As of March 2026, there have been no active drug shortage alerts from the FDA or EMA specifically related to paracetamol. However, the potential for future shortages remains if supply chain vulnerabilities are not addressed.

• Diversify API and KSM Sourcing: Establish relationships with multiple suppliers across different geographies to reduce dependency on a single source, particularly for critical raw materials like paracetamol KSMs.

• Maintain Strategic Inventory Buffers: Develop and maintain adequate stockpiles of essential APIs and KSMs to cushion against potential supply chain disruptions.

• Enhance Regulatory Compliance Across Markets: Ensure that manufacturing facilities meet the regulatory standards of all major export destinations to facilitate smoother market access and reduce the risk of export restrictions.

• Monitor PLI Scheme Developments: Stay informed about the progress and opportunities within India's PLI scheme for bulk drugs to leverage incentives aimed at boosting domestic API production.

• Implement Advanced Supply Chain Visibility Tools: Utilize technology to gain real-time insights into supply chain operations, enabling proactive identification and mitigation of potential risks.

RISK_LEVEL: MEDIUM